Anqi Xu

Anqi Xu

Auto-generated profile, based on publicly available information

Anqi Xu

Neurosurgery Center, Department of Cerebrovascular Surgery, The Engineering Technology Research Center of Education Ministry of China on Diagnosis and Treatment of Cerebrovascular Disease, Zhujiang Hospital, Southern Medical University, Guangzhou, People’s Republic of China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2021 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
AXAnqi Xu
Anqi Xu
XWXizhao Wang
Xizhao Wang
JLJie Luo
Jie Luo
MZMingfeng Zhou
Mingfeng Zhou
RYRenhui Yi
Renhui Yi
YSYe Song
Ye Song
The homeobox protein cut-like 1 (CUX1) comprises three isoforms and has been shown to be involved in the development of various types of malignancies. However, the expression and role of the CUX1 isoforms in glioma remain unclear. Herein, we first identified that P75CUX1 isoform exhibited consistent expression among three isoforms in glioma with specifically designed antibodies to identify all CUX1 isoforms. Moreover, a significantly higher expression of P75CUX1 was found in glioma compared with non-tumor brain (NB) tissues, analyzed with western blot and immunohistochemistry, and the expression level of P75CUX1 was positively associated with tumor grade. In addition, Kaplan–Meier survival analysis indicated that P75CUX1 could serve as an independent prognostic indicator to identify glioma patients with poor overall survival. Furthermore, CUX1 knockdown suppressed migration and invasion of glioma cells both in vitro and in vivo. Mechanistically, this study found that P75CUX1 regulated epithelial–mesenchymal transition (EMT) process mediated via β-catenin, and CUX1/β-catenin/EMT is a novel signaling cascade mediating the infiltration of glioma. Besides, CUX1 was verified to promote the progression of glioma via multiple other signaling pathways, such as Hippo and PI3K/AKT. In conclusion, we suggested that P75CUX1 could serve as a potential prognostic indicator as well as a novel treatment target in malignant glioma.

27 March 2020 in Bioscience Reports
Verified
Journal Article
Open access
PDF file
AXAnqi Xu
Anqi Xu
HYHuiping Yang
Huiping Yang
KGKunjie Gao
Kunjie Gao
ZZZhengming Zhan
Zhengming Zhan
ZSZibin Song
Zibin Song
YSYe Song
Ye Song
Aims: The dysregulation and essential role of WNTs in glioma have been widely implicated. However, there is a paucity of literature on the expression status of all the 19 WNTs in glioma. Our study was aimed to evaluate the expression and prognostic values of the 19 WNTs in glioma. Methods: mRNA expression and clinical data were retrieved from the Cancer Genome Atlas (TCGA) database, Chinese Glioma Genome Atlas (CGGA), GTEx and ONCOMINE databases. The 50 frequent neighbor genes of WNT5A and WNT10B were shown with PPI network, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. Results: We found that the mRNA expression of WNT5A was significantly higher in glioma; however, the WNT10B expression was significantly lower in glioma. Furthermore, the expression of WNT5A and WNT10B was associated with the clinicopathology of glioma. The survival analysis revealed that the higher expressions of WNT5A and WNT16 were associated poor overall survival (OS) in patients with glioma. Conversely, overexpression of WNT3, WNT5B, and WNT10B was associated with better OS. Finally, Go and KEGG analysis revealed WNT5A was associated with multiple signal translations, and crucial oncogenes (EGFR and MDM2) and 2 important tumor suppressors (PTEN and IKN4a/ARF) were found closely correlated with WNT5A in glioma. Conclusion: Among 19WNTs, WNT5A can serve as a candidate to diagnose and therapy glioma, while WNT10B might be valuable for anti-glioma research. The presumed direction was provided to explore the relation of WNTs signal and multiple pathways in glioma.

1 October 2025 in Stroke
Verified
Journal Article
Open access
XFXin Feng
Xin Feng
CHChi Huang
Chi Huang
XTXin Tong
Xin Tong
ZWZhuohua Wen
Zhuohua Wen
YZYajun Zhu
Yajun Zhu
CDChuanzhi Duan
Chuanzhi Duan
BACKGROUND: We aimed to determine the effects of statin treatment on outcomes of pipeline embolization device therapy for intracranial aneurysms in relation to LDL (low-density lipoprotein) cholesterol levels. METHODS: Using data from the SESIA registry (Safety and Efficacy of Stent Deployment for Intracranial Aneurysms), we enrolled participants who underwent pipeline embolization device implantation at 4 centers in China (2018–2022). Statin users (atorvastatin 20 mg daily, for ≥3 days and ≥6 months preprocedurally and postprocedurally, respectively) were matched with nonstatin users (1:1) using propensity scores and further adjusted by inverse probability of treatment weighting, balancing for baseline characteristics, procedural details, and lipid levels (based on East Asian profiles). Study outcomes include perioperative complications, aneurysmal occlusion, in-stent stenosis, and clinical prognosis at the latest follow-up. Multivariable analyses using logistic and Cox regression models adjusted for these factors in both prematched and postmatched cohorts, evaluating the role of lipid modification in subgroups. RESULTS: Of the 1558 patients screened, 1193 (53.75±11.07 years, 69.4% females; statin: n=603, nonstatin: n=590) were enrolled with 3- to 48-month follow-up. In the matched cohort (352 pairs), statin treatment reduced the incidences of perioperative cerebrovascular (2.0% versus 8.5%, P =0.001) and follow-up ischemic (1.7% versus 5.1%, P =0.020) complications. Multivariable analyses in participants with baseline LDL-cholesterol ≥2.59 mmol/L showed that statin treatment was associated with fewer perioperative cerebrovascular complications (odds ratio, 0.371 [95% CI, 0.195–0.705]; P =0.002), in-stent stenosis (hazard ratio, 0.433 [95% CI, 0.269–0.698]; P =0.001), and follow-up ischemic events (hazard ratio, 0.315 [95% CI, 0.135–0.733]; P =0.007; P values for interaction were 0.671, 0.009, and 0.507, respectively, versus <2.59 mmol/L). Postmatched analyses confirmed consistency for perioperative cerebrovascular complications (odds ratio, 0.416 [95% CI, 0.211–0.821]), in-stent stenosis (hazard ratio, 0.397 [95% CI, 0.232–0.667]), and follow-up ischemic events (hazard ratio, 0.364 [95% CI, 0.148–0.895]). CONCLUSIONS: Atorvastatin treatment improved postpipeline embolization device-deployment outcomes by reducing ischemic events, particularly in patients with elevated LDL-cholesterol. The long-term benefits of adjunctive statin use in this population warrant further investigation. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03387995.

17 October 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
ZWZhuohua Wen
Zhuohua Wen
XCXiheng Chen
Xiheng Chen
XTXin Tong
Xin Tong
CHChi Huang
Chi Huang
MHMengshi Huang
Mengshi Huang
XFXin Feng
Xin Feng
Flow diverter (FD) implantation is standard for unruptured intracranial aneurysms (UIAs), but cerebrovascular complications persist. This nested study within a prospective multicenter cohort evaluates whether short-term, low-dose glucocorticoid use is associated with cerebrovascular outcomes after FD implantation. Propensity-score matching with exact matching on UIA location yielded 1327 patients (360 glucocorticoid-treated; 967 controls). Intravenous glucocorticoids, initiated within 2 hours of the FD procedure and administered for ≥2 days, were associated with fewer in-hospital cerebrovascular events (6.9% vs. 13.1%; adjusted odds ratio [aOR], 0.53) and major cerebrovascular events (4.7% vs. 12.4%; aOR, 0.37). Over a median 2-year follow-up, glucocorticoid use was also associated with fewer new-onset major cerebrovascular events (3.6% vs. 8.7%; adjusted hazard ratio, 0.41) and less in-stent stenosis (7.9% vs. 13.2%; aOR, 0.55). Findings remained robust in unmatched patients on sensitivity analyses. We demonstrate that perioperative glucocorticoid regimens may reduce cerebrovascular events and in-stent stenosis in FD-treated patients, warranting randomized trials.

9 April 2021 in arXiv
Verified
Preprint
Open access
PDF file
XZXigou Zhang
Xigou Zhang
AXAnqi Xu
Anqi Xu
LGLi Guo
Li Guo
By means of a new notion of subforests of an angularly decorated rooted forest, we give a combinatorial construction of a coproduct on the free Rota-Baxter algebra on angularly decorated rooted forests. We show that this coproduct equips the Rota-Baxter algebra with a bialgebra structure and further a Hopf algebra structure.